Blade Therapeutics benefits from R&D Tax Incentives.

Setting up a biotech subsidiary of a US company in Australia needed Acclime’s guidance and support.

  • Client industry:
    Life sciences
  • Services:
    R&D Advisory, company registration, business compliance
  • Country:

Blade Therapeutics is advancing innovative anti-fibrotic therapies to meet currently unserved patient needs. Several rare/orphan and chronic debilitating conditions manifest with fibrosis, a complex, pathologic process in which healthy cells are replaced by progressively worsening scar tissue (fibrosis). They are committed to developing disease modifying and lifesaving treatments.

Acclime is a great business partner to work with. They offer a one-stop service to cover everything required to manage an Australian subsidiary.

Having worked with Acclime in two R&D incentive applications, I highly recommend Acclime to other biotech companies who are considering setting up a subsidiary in Australia.

Acclime has been instrumental in guiding us successfully through the R&D Tax Incentive program to conduct clinical trials in Australia. Even though I had prior experience in applying this program, I have relied heavily reply on Acclime to keep our company compliant and up to date with local changes.

Shirley Chiang
VP Finance, Blade Therapeutics

Not sure where to begin?

Schedule a free 30-minute discovery call to discuss starting & operating your company in Australia.

Blair Lucas, Acclime Partner

© Acclime Australia | Privacy policy

Liability limited by a scheme approved under Professional Standards Legislation.